ClinicalTrials.gg
RecruitingNCT07775378Updated Aug 20, 2026

Boron Levels, Oxidative Stress, and Inflammation in Periodontitis

An observational study in Periodontitis, sponsored by Marmara University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Marmara University · Observational

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
60
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This cross-sectional observational study aims to evaluate the relationship between boron levels and oxidative stress, antioxidant defense, and inflammatory markers in individuals with periodontitis. The study will include systemically healthy, non-smoking individuals divided into two groups: periodontally healthy controls and patients with Stage III-IV periodontitis. Boron levels and selected oxidative stress, antioxidant, and inflammatory biomarkers will be evaluated in saliva and gingival tissue samples. The findings will be compared between the groups to investigate the potential relationship between boron levels and periodontal inflammation and oxidative stress.

Read the detailed description

Periodontitis is a chronic inflammatory disease characterized by the destruction of the tooth-supporting tissues and is associated with an imbalance between oxidative stress and antioxidant defense mechanisms. Boron is a trace element that has been suggested to have potential roles in antioxidant and inflammatory processes; however, its relationship with periodontal disease remains unclear.

This cross-sectional observational study will include 60 systemically healthy, non-smoking participants: 30 periodontally healthy individuals and 30 patients diagnosed with Stage III-IV periodontitis. Periodontal clinical parameters will be recorded for all participants.

Unstimulated saliva samples will be collected before periodontal surgical procedures. Gingival tissue samples will be obtained during clinically indicated periodontal surgical procedures, including crown-lengthening procedures in periodontally healthy participants and periodontal surgery in participants with periodontitis.

Boron levels will be determined in saliva and gingival tissue samples. Oxidative stress and antioxidant defense will be evaluated using selected biomarkers, including reactive oxygen species, total oxidant status, malondialdehyde, total antioxidant status, glutathione, superoxide dismutase, and catalase. Interleukin-1 beta will be evaluated as an inflammatory marker.

Boron levels and biochemical parameters will be compared between periodontally healthy individuals and participants with periodontitis, and their relationships with periodontal clinical parameters, oxidative stress, antioxidant defense, and inflammation will be investigated.

02

Conditions studied

  • Periodontitis

Keywords

  • Boron
  • Oxidative Stress
  • Antioxidant Defense
  • Inflammation
  • Saliva
  • Gingival Tissue
03

In context

Periodontitis

1,231 studies on the registry are indexed under Periodontitis; 295 are open to participants now.

This study's planned enrollment of 60 is below the median of 90 across 372 observational studies indexed under Periodontitis.

Browse Periodontitis studies →

Lead sponsor

Marmara University is the lead sponsor of 599 studies on the registry; 138 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of 60 systemically healthy individuals aged 18-65 years attending the Department of Periodontology, Faculty of Dentistry, Marmara University. Participants will be divided into two groups: 30 individuals with Stage III-IV periodontitis with an indication for periodontal flap surgery and 30 periodontally healthy individuals with an indication for crown-lengthening surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Volunteering to participate in the study and signing the form
  • Being between 18 and 65 years of age
  • Being systemically healthy
  • No antibiotic use within the last 3 months
  • No periodontal treatment within the last 6 months
  • Being a non-smoker or having quit smoking at least 5 years ago
  • Not being pregnant or breastfeeding
  • No current use of , drugs, or non-steroidal anti-inflammatory drugs
  • No current use of medications associated with gingival enlargement, such as calcium channel blockers, phenytoin, or cyclosporine
  • No regular use of boron-containing supplements or multivitamin complexes
  • For the periodontally healthy group: no clinical attachment loss, bleeding on probing \<10%, probing depth ≤3 mm, no radiographic bone loss, and an indication for crown-lengthening surgery
  • For the periodontitis group: diagnosis of Stage III or IV periodontitis according to the 2017 World Workshop classification and an indication for periodontal flap surgery

Exclusion criteria

Exclusion Criteria:

  • Incomplete or unreliable clinical measurements
  • Insufficient saliva or gingival tissue sample for biochemical analyses
  • Regular use of boron-containing oral care products within the last 3 months
  • Regular consumption of boron-rich supplements or mineral waters
  • Failure to comply with the study protocol
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
60 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Periodontitis Group

    Systemically healthy, non-smoking individuals diagnosed with Stage III-IV periodontitis who are scheduled for clinically indicated periodontal surgical treatment.

    Other: Biochemical Assessment of Saliva and Gingival Tissue

  • Periodontally Healthy Group

    Systemically healthy, non-smoking individuals with periodontal health who are scheduled for clinically indicated crown-lengthening surgery.

    Other: Biochemical Assessment of Saliva and Gingival Tissue

Interventions

  • OtherBiochemical Assessment of Saliva and Gingival Tissue

    Unstimulated saliva and gingival tissue samples will be collected from participants. Gingival tissue samples will be obtained during clinically indicated periodontal surgical procedures. The samples will be biochemically analyzed to determine boron levels and markers of oxidative stress, antioxidant defense, and inflammation. No experimental treatment or therapeutic intervention will be administered as part of the study.

06

What researchers measure

Primary outcomes

  1. Boron Levels in Saliva and Gingival Tissue

    Boron levels will be measured in unstimulated saliva and gingival tissue samples obtained from participants in the periodontitis and periodontally healthy groups. Salivary boron levels will be expressed as µg/mL and gingival tissue boron levels as µg/g.

    Time frame: At the time of the clinically indicated periodontal surgical procedure

Secondary outcomes

  1. Oxidative Stress Markers

    Oxidative stress will be assessed by measuring reactive oxygen species (ROS), total oxidant status (TOS), and malondialdehyde (MDA) levels in samples obtained from the periodontitis and periodontally healthy groups.

    Time frame: At the time of the clinically indicated periodontal surgical procedure

  2. Antioxidant Defense Markers

    Antioxidant defense will be assessed by measuring total antioxidant status (TAS), glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT) levels in samples obtained from the periodontitis and periodontally healthy groups.

    Time frame: At the time of the clinically indicated periodontal surgical procedure

  3. Inflammatory Marker

    Inflammation will be assessed by measuring interleukin-1 beta (IL-1β) levels in samples obtained from the periodontitis and periodontally healthy groups.

    Time frame: At the time of the clinically indicated periodontal surgical procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared, as data sharing beyond the scope of the present study was not included in the approved study protocol and informed consent process.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Nov 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2026
First posted
Aug 20, 2026
StartActual
Feb 26, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Mar 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07775378
Lead sponsor
Marmara University
Responsible party
Sponsor
First posted
Aug 20, 2026
Start date
Feb 26, 2026
Primary completion
Nov 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Aug 20, 2026

Study contacts

LEYLA KURU
Contact
lkuru@marmara.edu.tr
+905363791443

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion